Construction of the plant will commence in 2025 with first production expected to be in 2027
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Subscribe To Our Newsletter & Stay Updated
